A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab, to Compare Efficacy at 16 Weeks With Placebo and to Assess Safety and Tolerability up to 52 Weeks in Chinese Participants With Active Non-radiographic Axial Spondyloarthritis
Latest Information Update: 27 May 2024
At a glance
- Drugs Secukinumab (Primary)
- Indications Axial spondyloarthritis; Non-radiographic axial spondyloarthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 23 Jan 2024 Status changed from recruiting to active, no longer recruiting.
- 08 Jan 2024 Planned End Date changed from 16 Apr 2025 to 6 Feb 2025.
- 08 Jan 2024 Planned primary completion date changed from 20 May 2024 to 8 Apr 2024.